Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of GRC 17536 in healthy volunteers
NL-OMON36129Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain, asthma, chronic obstructive pulmonary disease (COPD) and 1 more comparing GRC 17536 with Placebo (2 arms). Primary endpoints: Plasma pharmacokinetics of GRC 17536, Urine pharmacokinetics of GRC 17536 and 10 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
GRC-17536
03
Conditions
painasthmachronic obstructive pulmonary disease (COPD)chronic cough
Beyond the preview
Go deeper on NL-OMON36129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36129.